This challenge was overcome by developing resistant, synthetic GLP-1 receptor analogs (GLP1RAs) and DDP4-inhibitors, which are now routinely used in the management of type 2 diabetes [24]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.